Copyright
©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 7, 2010; 16(45): 5732-5738
Published online Dec 7, 2010. doi: 10.3748/wjg.v16.i45.5732
Published online Dec 7, 2010. doi: 10.3748/wjg.v16.i45.5732
Table 1 Characteristics of patients, relatives and control group subjects n (%)
CD (n = 64) | CD relatives (n = 25) | UC (n = 63) | UC relatives (n = 28) | Control (n = 34) | |
Sex | |||||
Male | 28 (43.8) | 9 (36.0) | 32 (50.8) | 11 (39.3) | 15 (44.1) |
Female | 36 (56.2) | 16 (64.0) | 31 (49.2) | 17 (60.7) | 19 (55.9) |
Age (yr, mean ± SD) | 37.93 ± 14.01 | 32.12 ± 14.31 | 38.74 ± 13.13 | 35.35 ± 17.07 | 38.58 ± 15.09 |
Disease duration (yr, mean ± SD) | 4.37 ± 3.61 | 4.03 ± 3.66 | |||
Disease location (CD) | |||||
Colon | 2 (3.1) | ||||
Ileum | 26 (40.6) | ||||
Ileocolonic | 36 (56.3) | ||||
Disease location (UC) | |||||
Proctitis | 9 (14.3) | ||||
Distal involvement | 24 (38.1) | ||||
Left colon invol | 9 (14.3) | ||||
Diffuse | 2 (3.2) | ||||
Pancolitis | 19 (30.2) | ||||
Disease type (CD) | |||||
Stricturing | 7 (10.9) | ||||
Penetrating | 6 (9.4) | ||||
Inflammatory | 51 (79.7) | ||||
Medications (for CD and UC) | |||||
No medication | 5 (7.8) | 5 (7.9) | |||
5-ASA | 57 (89.06) | 57 (90.4) | |||
Steroids | 5 (7.8) | 5 (7.9) | |||
AZA | 13 (20.3) | 8 (12.6) | |||
Antibiotics | 1 (1.6) | 3 (4.7) |
Table 2 Pancreatic antibody and anti-Saccharomyces cerevisiae positivity results in study groups n (%)
CD (n = 64) | UC (n = 63) | CD relatives (n = 25) | UC relatives (n = 28) | Control (n = 34) | |
PAB | 9 (14.1) | 5 (7.9) | 0 (0) | 0 (0) | 0 (0) |
ASCA | 37 (57.8) | 13 (20.6) | 9 (36) | 5 (17.9) | 6 (17.6) |
Table 3 Positivity rates of pancreatic antibody according to Vienna classification
A1 (n = 43, PAB = 7, 16.27%) | A2 (n = 21, PAB = 2, 9.52%) | |||||||
B1 (n = 31, PAB = 5, 16.12%) | B2 (n = 6, PAB = 1, 16.66%) | B3 (n = 6, PAB = 1, 16.66%) | B1 (n = 20, PAB = 2, 10%) | B2 (n = 1, PAB = 0, 0%) | B3 (n = 0, PAB = 0, 0%) | |||
L1 (n = 26, 3.84%) | A1 (n = 18, PAB = 1, 5.55%) | n = 15, PAB = 1, 6.66% | n = 0, PAB = 0, 0% | n = 3, PAB = 0, 0% | A2 (n = 8, PAB = 0, 0%) | n = 7, PAB = 0, 0% | n = 1, PAB = 0, 0% | n = 0, PAB = 0, 0% |
L2 (n = 2, 0%) | A1 (n = 1, PAB = 0, 0%) | n = 1, PAB = 0, 0% | n = 0, PAB = 0, 0% | n = 0, PAB = 0, 0% | A2 (n = 1, PAB = 0, 0%) | n = 1, PAB = 0, 0% | n = 0, PAB = 0, 0% | n = 0, PAB = 0, 0% |
L3 (n = 36, 22.22%) | A1 (n = 24, PAB = 6, 25%) | n = 15, PAB = 4, 25% | n = 6, PAB = 1, 16.66% | n = 3, PAB = 1, 33.33% | A2 (n = 12, PAB = 2, 16.66%) | n = 12, PAB = 2, 16.66% | n = 0, PAB = 0, 0% | n = 0, PAB = 0, 0% |
Table 4 Positivity rates of anti-Saccharomyces cerevisiae according to Vienna classification
A1 (n = 43, ASCA = 27, 62.79%) | A2 (n = 21, ASCA = 10, 47.61%) | |||||||
B1 (n = 31, ASCA = 18, 58.06%) | B2 (n = 6, ASCA = 3, 50%) | B3 (n = 6, ASCA = 6, 100%) | B1 (n = 20, ASCA = 9, 45%) | B2 (n = 1, ASCA = 1, 100%) | B3 (n = 0, ASCA = 0, 0%) | |||
L1 (18/26, 69.23%) | A1 (n = 18, ASCA = 13, 72.22%) | n = 15, ASCA = 10, 66.66% | n = 0, ASCA = 0, 0% | n = 3, ASCA = 3, 100% | A2 (n = 8, ASCA = 5, 62.5%) | n = 7, ASCA = 4, 57.14% | n = 1, ASCA = 1, 100% | n = 0, ASCA = 0, 0% |
L2 (0/2, 0%) | A1 (n = 1, ASCA = 0, 0%) | n = 1, ASCA = 0, 0% | n = 0, ASCA = 0, 0% | n = 0, ASCA = 0, 0% | A2 (n = 1, ASCA = 0, 0%) | n = 1, ASCA = 0, 0% | n = 0, ASCA = 0, 0% | n = 0, ASCA = 0, 0% |
L3 (19/36, 52.77%) | A1 (n = 24, ASCA = 14, 58.33%) | n = 15, ASCA = 8, 53.33% | n = 6, ASCA = 3, 50% | n = 3, ASCA = 3, 100% | A2 (n = 12, ASCA = 5, 41.66%) | n = 12, ASCA = 5, 41.66% | n = 0, ASCA = 0, 0% | n = 0, ASCA = 0, 0% |
Table 5 Pancreatic antibody and anti-Saccharomyces cerevisiae positivity according to Crohn’s disease activity index n (%)
Disease activity according to CDAI | PAB | ASCA | Total | ||
Negative | Positive | Negative | Positive | ||
Mild (< 150 points) | 49 (84.5) | 9 (15.5) | 27 (46.6) | 31 (53.4) | 58 (100) |
Moderate (150-450 points) | 5 (100) | 0 (0) | 0 (0) | 5 (100) | 5 (100) |
Severe (> 450 points) | 1 (100) | 0 (0) | 0 (0) | 1 (100) | 1 (100) |
Total | 55 | 9 | 27 | 37 | 64 |
- Citation: Demirsoy H, Ozdil K, Ersoy O, Kesici B, Karaca C, Alkim C, Akbayir N, Erdem LK, Onuk MD, Beyzadeoglu HT. Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives. World J Gastroenterol 2010; 16(45): 5732-5738
- URL: https://www.wjgnet.com/1007-9327/full/v16/i45/5732.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i45.5732